Literature DB >> 7787251

Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells.

F J Geoffroy1, C J Allegra, B Sinha, J L Grem.   

Abstract

Recombinant human interleukin-1 alpha (rIL-1 alpha), at concentrations that were not growth-inhibitory when given alone (100-10,000 U/ml), enhanced the growth inhibition resulting from a 72-h fluorouracil (FUra) exposure in HCT116 colon cancer cells. Median-effect analysis of clonogenic assays indicated that rIL-1 alpha, given 24 h prior to and following a 24-h exposure to FUra, increased lethality in a more than additive fashion. rIL-1 alpha did not appear to significantly affect [3H]-FUra metabolism, total [3H]-FUra-RNA incorporation or RNA retention after drug removal, inhibition of thymidylate synthase, or thymidine triphosphate pool depletion. During continuous exposure to rIL-1 alpha, transient stimulation of RNA and DNA synthesis was observed at 72 h, with a return to normal by 96 h. A 24-h exposure to 10 microM FUra altered the elution profile of newly synthesized DNA as monitored by pH step alkaline elution. An accumulation of lower-MW single-stranded DNA species was noted with FUra compared to control, accompanied by a significantly decreased proportion of DNA retained on the polycarbonate filter: 10% retained vs. 32% for control (P = 0.01). A 48-h exposure to rIL-1 alpha alone did not affect the elution profile of nascent DNA species, nor did it enhance the effects of FUra. Although FUra did not appreciably affect pulse [3H]-uridine incorporation into RNA for the initial 8-24 h of FUra exposure, progressive inhibition of net RNA synthesis was observed thereafter. FUra prevented the stimulatory effect of rIL-1 alpha on RNA synthesis, and net RNA synthesis was significantly inhibited (by 64-79% after 72 and 96 h) with the combination compared to rIL-1 alpha alone. Continuous exposure to 10 microM thymidine did not rescue cells from the lethality of FUra alone or the combination of FUra plus rIL-1 alpha, suggesting that depletion of deoxythymidine triphosphate as a consequence of thymidylate synthase inhibition was not the most important component of FUra toxicity. In contrast, 1 mM uridine provided partial protection against the toxicity of FUra alone or with rIL-1 alpha. Although uridine did not affect FUra metabolism, it decreased FUra-RNA incorporation by 42-60%, presumably as a consequence of the 2-fold expansion of UTP pools. [125I]-rIL-1 alpha binding was nonspecific; with a 24-h exposure, however, internalized [125I]-rIL-1 alpha exceeded cell surface-bound material by 2-fold.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7787251

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  11 in total

1.  Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity.

Authors:  Deliang Cao; Amy Ziemba; James McCabe; Ruilan Yan; Laxiang Wan; Bradford Kim; Michael Gach; Stuart Flynn; Giuseppe Pizzorno
Journal:  Mol Cancer Ther       Date:  2011-09-27       Impact factor: 6.261

2.  MDMX regulation of p53 response to ribosomal stress.

Authors:  Daniele M Gilkes; Lihong Chen; Jiandong Chen
Journal:  EMBO J       Date:  2006-11-16       Impact factor: 11.598

3.  CD8 alpha-deficient mice are highly susceptible to 5-fluorouracil-induced lethality.

Authors:  Naoto Itoh; Hitoshi Nishimura; Tetsuya Matsuguchi; Toshiki Yajima; Yasuji Mokuno; Takashi Hiromatsu; Yuji Nimura; Yasunobu Yoshikai
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

4.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents.

Authors:  F Bunz; P M Hwang; C Torrance; T Waldman; Y Zhang; L Dillehay; J Williams; C Lengauer; K W Kinzler; B Vogelstein
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

5.  Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation.

Authors:  D M Pritchard; A J Watson; C S Potten; A L Jackman; J A Hickman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

Review 6.  5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.

Authors:  J L Grem
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

7.  Cancer stem cell and stromal microenvironment.

Authors:  Li Li; John Cole; David A Margolin
Journal:  Ochsner J       Date:  2013

8.  Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines.

Authors:  Manish Patel; Ram Agarwal; Bach Ardalan
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-15       Impact factor: 4.553

Review 9.  Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.

Authors:  Peter M Wilson; Peter V Danenberg; Patrick G Johnston; Heinz-Josef Lenz; Robert D Ladner
Journal:  Nat Rev Clin Oncol       Date:  2014-04-15       Impact factor: 66.675

Review 10.  2b or Not 2b: How Opposing FGF Receptor Splice Variants Are Blocking Progress in Precision Oncology.

Authors:  Richard J Epstein; Li Jun Tian; Yan Fei Gu
Journal:  J Oncol       Date:  2021-04-30       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.